Thread by @aishaikh

‼️Effect of Finerenone on CKD outcomes in T2DM

⚡️Finerenone decreased risk of CKD progression by 18%

⚡️Finerenone decreased CV morbidity & mortality by 14%

Published in @NEJM today

nejm.org/doi/full/10.10…

@ASNKidney #Kidneywk

💥How does Finerenone work?
(These Slides are from the ASN Kidney Week: High Impact Clinical Trial Session)

💥Trial eligibility criteria👇🏽

💥Study Design👇🏽

💥Baseline Demographics & Medications👇🏽

💥Baseline eGFR and UACR

💥Change in UACR: 31% reduction with Finerenone at 4 months versus placebo

💥BP and HbA1c changes in the Finerenone and placebo groups

‼️18% reduction in the Primary Kidney Composite Endpoint in the
Finerenone group versus the Placebo group (p = 0.0014)

💥Numbers Needed to Treat (NNT)
for Primary and Secondary endpoints over 3 years

💥Adverse Events and Change in Serum Potassium over time

💥Adverse events related to Hyperkalemia such as permanent drug discontinuation, hospitalization and death

💥Adverse events related to Acute Kidney Injury

💥Safety Summary of Finerenone

💥How drug discontinuation due to Hyperkalemia in FIDELIO-DKD Trial compare to the ALTITUDE & VA-NEPHRON-D Trials where dual RAS Blockade was used in DKD populations?

💥How did drug discontinuation due to Hyperkalemia in FIDELIO-DKD Trial compare to the AMBER Trial where Patiromer was used with Spironolactone + ACEi/ARB in CKD population?

💥FIDELIO-DKD Trial Conclusions
#FIDELIODKD